Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 30, 2019 06:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Top-Line Results of CMS-001, a Phase 3 Trial of Firdapse® (Amifampridine Phosphate) in Patients with Congenital Myasthenic Syndromes (CMS)

CMS-001 trial is the first and only double-blinded, placebo-controlled study ever conducted in genetically confirmed CMS patients Results in full population across all tested subtypes of CMS did...
September 25, 2019 08:02 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Participate in the 2019 Cantor Global Healthcare Conference

CORAL GABLES, Fla., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative...
September 23, 2019 14:55 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc. Comments on Trading in its Common Stock and on its Capital Resources

CORAL GABLES, Fla., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX) is commenting on today's trading activity in its common stock and on the current state of its...
September 13, 2019 06:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc. Determines Not to Proceed with Previously Announced Public Offering of Common Stock

CORAL GABLES, Fla., Sept. 13, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX) today announced that it will not conclude the offering of shares of its common stock announced...
September 11, 2019 16:19 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

CORAL GABLES, Fla., Sept. 11, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX) announced today that it has commenced an underwritten public offering of 8.0 million shares of...
August 28, 2019 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Participate in the 14th Annual Citi Biotech Conference on September 4th, 2019

CORAL GABLES, Fla., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative...
August 07, 2019 16:18 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Second Quarter 2019 Financial Results and Provides Corporate Update

Firdapse® Launch Momentum Continues with Second Quarter Net Revenues of $28.8 Million 409 Adult LEMS Patients Active on Firdapse as of June 30, 2019 Company to Host Quarterly Conference Call at 8:30...
August 01, 2019 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Its Support of Spinal Muscular Atrophy Awareness Month

CORAL GABLES, Fla., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative...
July 31, 2019 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Hold Second Quarter 2019 Financial Results Conference Call and Webcast on Thursday, August 8th, 2019

CORAL GABLES, Fla., July 31, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative...
June 12, 2019 08:47 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Files Federal Lawsuit Against U.S. Food and Drug Administration

CORAL GABLES, Fla., June 12, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), today announced it has filed a suit against the U.S. Food and Drug Administration (FDA)...